Paris - Delayed Quote EUR

OSE Immunotherapeutics SA (OSE.PA)

1.8800 -0.0720 (-3.67%)

As of 4:39:02 PM GMT+1. Market Open.

OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

GlobeNewswire 3d ago

OSE.PA
-3.67%
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

GlobeNewswire 14d ago

OSE.PA
-3.67%
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference

GlobeNewswire 18d ago

OSE.PA
-3.67%
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update

GlobeNewswire 1mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting

GlobeNewswire 1mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026

GlobeNewswire 2mo ago

OSE.PA
-3.67%
OSE
Half-Year Report on Liquidity Contract with Invest Securities

GlobeNewswire 3mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting

GlobeNewswire 4mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing

GlobeNewswire 5mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

GlobeNewswire 5mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position

GlobeNewswire 6mo ago

OSE.PA
-3.67%
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients

GlobeNewswire 6mo ago

OSE.PA
-3.67%

U.S. markets close in 4h 20m

OSE Immunotherapeutics SA (OSE.PA)

OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference

OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update

OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting

OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026

Half-Year Report on Liquidity Contract with Invest Securities

OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients